The thesis
Three things shifted at roughly the same time. (1) The open-source biomedical model stack — protein structure, neoantigen prediction, drug-mutation matching, RNA-seq — became good enough and cheap enough that a small team can run a precision-oncology workup on any patient. (2) USDA-CVB opened a conditional-licensure path for autologous therapeutic biologics, which means novel personalized treatments can reach real patients without waiting decades. (3) Comparative oncology has finally been taken seriously: dogs get the same cancers humans do, and what we learn in dogs accelerates human oncology.
Why a unified portal
Today, even when all the right pieces exist, they live in different places. Genomics is at one vendor. Imaging is at another. The biopsy report is a PDF in your email. The chemo schedule is in your vet's practice management system. The symptom log, if it exists at all, is on a Post-it on your fridge. Owners stitch all this together at the worst possible time. We don't think they should have to.
Our role with your dog
SciRouter Oncology is decision-support, not a diagnostic device. The licensed veterinarian on your dog's case retains full clinical authority and prescribing responsibility. What we add is the common workspace: the same record visible to you, your GP, and your specialty oncologist, with the open-source biomedical model stack running underneath when it's useful.
Our role with research
If — and only if — you opt in, your dog's de-identified record helps researchers and vets find treatments faster. The data flywheel is owner-controlled, owner-revocable, and audit-logged. We do not sell records to pharma; we publish from the cohort and collaborate with academic medical centers on comparative oncology trials.
Who we are
SciRouter Oncology is a vertical of SciRouter, the unified API for scientific computing. We were already routing the open-source biomedical model stack for drug-discovery customers when Rosie's story in March 2026 made it clear the same stack should be available, in workspace form, to every family with a dog facing cancer.
Where we go next
Phase 0: the public information surface and signup, live now. Phase 1: owner + vet portals with document parsing and cohort comparator. Phase 2: genomics ingestion from any lab. Phase 3: personalized mRNA neoantigen vaccine pilot under university partnership and USDA-CVB conditional licensure. Phase 4: comparative oncology clinical trials feeding human Phase I/II target selection. The strategy is the science, and the workspace is the wedge that gets us there.